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Abstract
Multiple endocrine neoplasia type 1 (MEN1), an autosomal dominant disorder caused 
by MEN1 germline mutations, is characterised by parathyroid, pancreatic and pituitary 
tumours. MEN1 mutations also cause familial isolated primary hyperparathyroidism (FIHP), 
a milder condition causing hyperparathyroidism only. Identical mutations can cause 
either MEN1 or FIHP in different families, thereby implicating a role for genetic modifiers 
in altering phenotypic expression of tumours. We therefore investigated the effects of 
genetic background and potential for genetic modifiers on tumour development in adult 
Men1+/- mice, which develop tumours of the parathyroids, pancreatic islets, anterior 
pituitary, adrenal cortex and gonads, that had been backcrossed to generate C57BL/6 
and 129S6/SvEv congenic strains. A total of 275 Men1+/- mice, aged 5–26 months were 
macroscopically studied, and this revealed that genetic background significantly influenced 
the development of pituitary, adrenal and ovarian tumours, which occurred in mice over 
12 months of age and more frequently in C57BL/6 females, 129S6/SvEv males and  
129S6/SvEv females, respectively. Moreover, pituitary and adrenal tumours developed 
earlier, in C57BL/6 males and 129S6/SvEv females, respectively, and pancreatic and 
testicular tumours developed earlier in 129S6/SvEv males. Furthermore, glucagon-positive 
staining pancreatic tumours occurred more frequently in 129S6/SvEv Men1+/- mice. Whole 
genome sequence analysis of 129S6/SvEv and C57BL/6 Men1+/- mice revealed >54,000 
different variants in >300 genes. These included, Coq7, Dmpk, Ccne2, Kras, Wnt2b, Il3ra and 
Tnfrsf10a, and qRT-PCR analysis revealed that Kras was significantly higher in pituitaries 
of male 129S6/SvEv mice. Thus, our results demonstrate that Kras and other genes could 
represent possible genetic modifiers of Men1.
Introduction
Multiple endocrine neoplasia type 1 (MEN1) is an 
autosomal dominant disorder characterised by the 
occurrence of parathyroid, pancreatic islet and anterior 
pituitary tumours. In addition, some patients may also 
develop adrenal cortical tumours, carcinoids, facial 
angiofibromas, collagenomas and lipomas (1). MEN1-
associated tumours show a loss of heterozygosity of the 
MEN1 gene, which is located on chromosome 11q13 
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and encodes the ubiquitously expressed, predominantly 
nuclear scaffold tumour-suppressor protein, menin 
(2, 3, 4). Over 1500 MEN1 mutations have been reported, 
and 97% of these are associated with the simultaneous 
occurrence of the many tumours of the MEN1 syndrome, 
while the remaining 3% of mutations are associated with 
familial isolated hyperparathyroidism (FIHP), a disorder 
characterised by the sole occurrence of parathyroid 
tumours (5). Thirty such MEN1 mutations have been 
reported in patients with FIHP, and 15 of these mutations 
are identical to those reported in MEN1 patients and 
include intragenic deletions, gross deletions, intragenic 
insertions, missense, nonsense and splice site mutations 
(4, 5); thereby indicating that the same MEN1 mutations 
may cause MEN1 or FIHP in unrelated families. Overall, 
these findings implicate a role of modifier genes in altering 
the expression of MEN1 mutations (6, 7).
Genetic modifiers have been identified to influence 
the phenotypic manifestation of human diseases, as 
illustrated by studies of patients with DiGeorge syndrome 
type 1 (DGS1) (8). Patients with DGS1 typically suffer 
from hypoparathyroidism, immunodeficiency due to 
thymic aplasia, congenital heart defects and deformities 
of the ear, nose and mouth (9). Approximately 30% of 
patients may also have neurodevelopmental anomalies 
and urogenital malformations including unilateral 
agenesis, renal dysplasia, hydronephrosis and uterine 
didelphys with duplication of the cervix (8, 10, 11). DGS1 
is associated with deletions of chromosome 22q11.2, and 
abnormalities of T-box transcription factor 1 (TBX1) are 
found in >95% of DGS1 patients, although these do not 
explain the phenotypic variability observed in the renal 
and urinary tract abnormalities. However, additional 
studies revealed that a major driver of renal disease in 
DGS1 is CRK-like proto-oncogene, adaptor protein (CRKL), 
mutations of which sensitise the genetic background and 
modify the penetrance of congenital kidney and urinary 
tract anomalies in DGS1 patients (8).
In addition, studies of mutant mouse models for human 
disorders have also identified roles for genetic modifiers, 
in affecting the penetrance, dominance, expressivity and 
pleiotrophy of disease manifestations (12, 13). For example, 
studies of mutant mouse models have revealed that the 
secretory type II phospholipase A2 (Pla2s) gene is a major 
modifier of the adenomatous polyposis coli (APC) gene, 
such that its absence is associated with increased numbers of 
intestinal polyps in APC mutant mice that are on a C57BL/6J 
background, which are null for Pla2s activity, when compared 
to the APC mutant mice on MA/MyJ or Mus castaneus (CAST) 
backgrounds that highly express Pla2s (average number of 
intestinal polyps C57BL /6J:M A/MyJ :CAST = 28 .5:5. 7:3.0 ) 
(14). Furthermore, embryonic lethality and survival in mice 
associated with null mutations of several genes have been 
shown to be strain dependent, and studies of these mice have 
allowed mapping of modifier loci, for example, investigation 
of: transforming growth factor beta 1 null mice (Tgfb1-/-), 
which have vascular defects similar to those in patients 
with hereditary haemorrhagic telangiectasia, bred on NIH/
Ola and C57BL/6J/Ola backgrounds revealed the presence 
of a major codominant modifier gene for embryonic 
lethality on mouse proximal chromosome 7 (15); cystic 
fibrosis transmembrane conductance regulator null mice 
(CftrM1HSC/CftrM1HSC), which usually died of intestinal 
obstruction similar to that observed in patients with cystic 
fibrosis, bred on C57BL/6J and BALB/cJ backgrounds, 
revealed a modifier on mouse chromosome 7 that was 
associated with prolonged survival, likely due to a partial 
rectification of the Na+ and Cl- transport abnormalities 
(16); and p53 null mice (p53-/-) which develop multiple 
tumours similar to those in patients with the Li-Fraumeni 
syndrome (e.g. soft tissue sarcomas, osteosarcomas, breast 
cancer, brain tumours, leukaemia and adrenocortical 
carcinomas), bred on CE/J and 129/Sv backgrounds revealed 
the presence of a modifier for embryonic lethality on mouse 
chromosome 11 (17).
The influence of genetic background on the 
phenotypes of embryonic lethality and neural defects 
has also previously been reported in homozygous Men1-/-  
mouse embryos (18), implicating a role for genetic 
modifiers in MEN1 syndrome. Survival time of Men1-/- 
embryos was found to be significantly lower in the 129S6/
SvEv strain compared with the C57BL/6 strain and neural 
tube defects were exclusively found in the 129S6/SvEv 
embryos, while widespread oedema was specific to the 
C57BL/6 strain (18). However, the influence of genetic 
background and potential role of genetic modifiers 
on the development of tumours in adult Men1+/- mice 
have not been previously studied. Identification of such 
modifiers of tumour expression could provide a better 
understanding of the function of menin and its molecular 
interactions in endocrine tumourigenesis. We have 
previously established a conventional mouse knockout 
model of MEN1 on a mixed 129S6/SvEv and C57BL/6 
background, whereby Men1+/- mice develop tumours of the 
parathyroids, pancreatic islets, anterior pituitary, adrenal 
cortex and testes or ovaries by the age of 12 months (19). 
We therefore utilised this model to investigate the role of 
genetic background on tumour formation in adult Men1+/- 
mice, by carrying out backcrosses to generate Men1+/- mice 
on congenic C57BL/6 and 129S6/SvEv strain backgrounds.
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Materials and methods
Generation of Men1+/- congenic mouse strains and 
assessments of their genotypes and phenotypes
Mice were kept in accordance with UK Home Office 
guidelines and project license restrictions. Men1+/- /Men1+/+ 
mouse crosses were used as Men1-/- mice are not viable 
(18, 19). Genotypes of mice were determined by PCR 
analysis using DNA extracted from tail or ear biopsies and 
Men1 gene-specific primers, as previously reported (20). 
Primers Men1F (5′-TAGATGTAGCTGGATGGTGATGG-3′) 
and Men1R (5′-ATGAAGCTGAGGAGATGATGTAG-3′) 
yielded a 582 base-pair WT fragment and primers Men1F 
and NeoR (5′-GCTGACCGCTTCCTCGTG-3′) yielded a 
809 base-pair mutant fragment (Supplementary Fig. 1, 
see section on supplementary materials given at the end 
of this article). In total, 2358 mice were generated, and 
these comprised breeding cohorts and all genotypes from 
the background strains. A subset of these Men1+/- mice 
and Men1+/+ littermates were aged to 5 to 26 months and 
complete necropsy was performed. At necropsy, endocrine 
organs, including the pituitary, pancreas, adrenal, ovaries 
and testes, were inspected for abnormalities, as previously 
described (19). Macroscopic appearances were recorded and 
measurements of tumours or other abnormal masses made. 
Tissues were dissected and fixed in 4% paraformaldehyde 
(PFA) for 24 h, for histological and immunohistochemical 
analysis, as previously described (19). Endocrine organs 
with and without gross abnormalities were collected 
separately. Parathyroid tumours were not included in this 
study, as owing to their small size they cannot be detected 
by macroscopic examination.
Histology and immunohistochemistry
Paraffin embedded sections were dewaxed and rehydrated 
prior to staining. For H&E staining, haematoxylin (Modified 
Mayer’s Formula, Vector Laboratories, Peterborough, 
UK) was applied, followed by counterstaining with 1% 
eosin and permanent mounting (Vector Laboratories 
mounting media), as previously described (19). For 
immunohistochemical staining, antigen retrieval was 
performed using citrate buffer (0.1 M, pH 6.0) or High 
pH Antigen Retrieval Solution (Vector Laboratories), with 
heating (autoclave; 121°C for 10 min) or a combination of 
heating and pressure (antigen decloaking chamber). Tissue 
was blocked using 0.3% hydrogen peroxide/methanol and 
10% serum from the secondary antibody host. Primary 
antibodies included: anti-menin (AbCam ab2605); anti-
prolactin (National Hormone and Peptide Programme, 
Torrance, CA, USA); anti-growth hormone (AbCam ab8490); 
anti-chromogranin A (AbCam ab301704); anti-insulin 
(AbCam ab7842); anti-glucagon (AbCam ab10561971) and 
anti-Kras (AbCam ab84573). All HRP-conjugated secondary 
antibodies (Jackson Laboratories) were applied for 1 h, 
followed by 3,3′-diaminobenzidine (DAB) substrate (Vector 
Laboratories) for <5 min, and sections were counterstained 
with haematoxylin, as previously described (21). Sections 
were imaged and captured using an Eclipse E400 microscope 
(Nikon) and DXM1200C digital camera and NIS-Elements 
BR 2.30 software (both Nikon) (19, 22).
Whole genome sequence analysis
DNA was extracted from ear biopsies of C57BL/6J and 
129S6/SvEv mice using the Blood Core II kit (Qiagen) and 
used to generate a library for whole genome sequencing 
(WGS) that ustilised the Illumina HiSeq platform at 
the Oxford Genomics Centre (Wellcome Trust Centre 
for Human Genetics, University of Oxford), and single 
nucleotide variants called, as previously described (23). 
The generated gene lists were analysed using the Protein 
Analysis Through Evolutionary Relationship (PANTHER) 
system (http://pantherdb.org) (24).
Quantitative reverse transcription PCR (qRT-PCR)
Pituitary, ovary and testes tissues were harvested 
and placed immediately into RNAlater solution (Life 
Technologies). Pancreatic islets were picked from 
pancreatic tissue digested following direct intra pancreatic 
injection of 2 mL of 0.2 mg/mL Liberase (Roche) and 
placed immediately into RNAlater solution (25). Total 
RNA was extracted from the tissues using the RNeasy kit 
(Qiagen), and up to 1µg of total RNA was used to generate 
cDNA using the Quantitect RT kit (Qiagen), as described 
(26). Quantitect primers (Qiagen) were used for qRT-PCR 
reactions, which utilised the Quantitect SYBR green kit 
(Qiagen), on a RotorGene 5 (Qiagen), as described (26). 
Each test sample was normalized to the geometric mean 
of reference genes GAPDH, calnexin and α-tubulin. The 
relative expression of target cDNA in all qRT-PCR studies 
was determined using the Pfaffl method (27).
Western blot analysis
Mouse pituitaries were lysed in NP40 lysis buffer and 
prepared in 4× Laemmli loading dye, as previously 
described (26). Samples were resolved using 10% SDS-
PAGE gel electrophoresis, transferred to polyvinylidene 
difluoride membrane, probed with primary antibodies 
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(Calnexin-AB2301 (Millipore), Kras-ab84573 (AbCam)) and 
an anti-rabbit HRP-conjugated secondary antibody (Santa 
Cruz Biotechnology) and then visualised using Pierce ECL 
Western Blotting substrate (Thermo Fisher Scientific), as 
previously described (26). Calnexin protein expression 
was used as a loading control. Densitometry analysis was 
performed by calculating the number of pixels per band 
using ImageJ software (NIH). Data were represented as 
the number of pixels of the protein band, relative to the 
number of pixels of the corresponding calnexin band.
Statistical analysis
GraphPad Prism was used for the statistical analyses and 
the generation of graphs. The total proportion of Men1+/-  
mice with tumours, including tumour subtypes, was 
compared between two different genetic backgrounds 
by performing a Fisher’s exact test, with the threshold 
for statistical significance set at P < 0.05. A Bonferroni 
correction was applied to account for multiple tests. To 
evaluate the trend of tumour development, a Chi squared 
test for trends was applied. For all other analyses one-way 
ANOVA or t-tests were used, as previously described (26).
Results
Development of tumours in congenic Men1+/- mice
A total of 2358 mice (1166 Men1+/+ and 1192 Men1+/- mice) 
on 129S6/SvEv (n = 1166) and C57BL/6 (n = 1192) genetic 
background strains and backcross generations 10–18 were 
produced. There were no significant differences in the live 
births or survival to age 18–21 months between the Men1+/- or 
Men1+/+ mice or between the background strains (live births: 
Men1+/+ (n = 600 129S6/SvEv; n = 566 C57BL/6) vs Men1+/- 
(n = 566 129S6/SvEv; n = 626 C57BL/6); and survival: Men1+/+ 
(n = 146 129S6/SvEv; n = 95 C57BL/6) vs Men1+/- (n = 135 
129S6/SvEv; n = 149 C57BL/6) (Supplementary Tables 1 and 
2)). From these, a total of 275 Men1+/- mice from 129S6/
SvEv (n = 137) and C57BL/6 (n = 138) genetic background 
strains, aged 5–26 months, were macroscopically assessed 
for the prevalence of endocrine tumours in the pancreas, 
pituitary, adrenals and gonads. This age range was chosen as 
our previous study indicated that mice develop a significant 
number of tumours after 12 months of age, although 
tumours can be identified as early as 3 months of age (19). 
The number of tumours that developed and the organs 
affected increased with the age of the mice, consistent with 
the manifestations of the MEN1 syndrome in patients. 
However, the frequency of tumour development and age 
of onset depended on the background strain and sex of the 
mice. Thus, overall, more pituitary tumours developed in 
female C57BL/6 Men1+/- mice than in female 129S6/SvEv 
Men1+/- mice, while more adrenal tumours developed in 
male 129S6/SvEv Men1+/- than in male C57BL/6 Men1+/-  
mice and more ovarian tumours developed in 129S6/SvEv 
Men1+/- mice than in C57BL/6 Men1+/- mice (Table 1). When 
examined by age, significant differences were identified in 
the age of onset of these tumours, with: pituitary tumours 
occurring significantly earlier in male C56BL/6 Men1+/-
 mice (P < 0.005), when compared to 129S6/SvEv Men1+/- 
mice; pancreatic tumours occurring significantly earlier in 
male 129S6/SvEv than in C57BL/6 Men1+/- mice (P < 0.05); 
adrenal tumours occurring significantly earlier in female 
129S6/SvEv Men1+/- mice than in C57BL/6 Men1+/- mice 
(P < 0.005) and testicular tumours occurring significantly 
earlier in male 129S6/SvEv Men1+/- than in C57BL/6 Men1+/-  
mice (P < 0.005) (Fig. 1). The occurrence of these tumours is 
described in more detail subsequently.
Pituitary tumours in 129S6/SvEv and C57BL/6 
Men1+/- mice
Pituitary tumours were observed in the Men1+/- mice at 
necropsy, from the age of 13 months in the 129S6/SvEv 
strain and from 15 months of age in the C57BL/6 strain 
(Fig. 1). Histological and immunohistochemical analysis 
confirmed loss of menin expression in pituitary tumours 
(n = 4) from C57BL/6 Men1+/- and 129S6/SvEv Men1+/-  
mice and expression of prolactin, growth hormone and 
chromogranin A (Fig. 2). The anterior pituitary tumours were 
Table 1 Occurrence of endocrine tumours observed in 12- to 
26-month-old Men1+/- mice in 129S6/SvEv and C57BL/6 strains.
Tumours
Strain
P129S6/SvEv C57BL/6
Pituitary
 F 27/71 (38.0%) 56/74 (75.7%) <0.0001
 M 9/45 (20.0%) 8/43 (18.6%) NS
Pancreas
 F 66/71 (93.0%) 62/74 (83.8%) NS
 M 41/45 (91.1%) 41/43 (95.3%) NS
Adrenal
 F 7/71 (9.9%) 6/74 (8.1%) NS
 M 14/45 (31.1%) 5/43 (11.6%) 0.0376
Ovaries
 F 23/71 (32.4%) 8/74 (10.8%) 0.0021
Testes
 M 29/45 (64.4%) 28/43 (65.1%) NS
Data are shown as the number of mice with tumours/total number of 
mice examined, with the percentage in parenthesis. Results are based on 
macroscopic findings at necropsy.
F = female; M = male; NS = not significant.
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significantly more frequent in the female Men1+/- mice than 
in male Men1+/- mice (129S6/SvEv females vs males = 38% 
vs 20.0%, P < 0.005, and C57BL/6 females vs males = 75.7% 
vs 18.6%, P < 0.0001) (Table 1). In addition, significantly 
more C57BL/6 female Men1+/- mice had pituitary tumours 
than 129S6/SvEv female Men1+/- mice (75.7% vs 38.0%, 
P < 0.0001) (Table 1), whereas there was no significant 
difference in the number of anterior pituitary tumours in 
male Men1+/- mice between the two strains (Table 1).
Pancreatic neuroendocrine tumours in 129S6/SvEv 
and C57BL/6 Men1+/- mice
Pancreatic neuroendocrine tumours (PNETs) were the 
most frequent tumour type observed at necropsy and were 
detected in >85% of 129S6/SvEv and C57BL/6 Men1+/-mice 
(Table 1). The occurrence of PNETs was not significantly 
different between the two strains or between sexes (Table 1). 
A total of 25 PNETs (10 from 129S6/SvEv (n = 4 male and 
n = 6 female) and 15 from C57BL/6 (n = 2 male and n = 14 
female) Men1+/- mice were analysed by histology and 
immunohistochemistry, which confirmed loss of menin 
expression, but presence of chromogranin A expression 
(Fig. 3A). This analysis also revealed the occurrence of 
multiple PNETs (range = 1–9 PNETs per mouse) that varied 
in size in the 129S6/SvEv and C57BL/6 Men1+/-mice. 
Some tumours expressed insulin, while others expressed 
glucagon (Fig. 3A), and one C57BL6 and six 129SvEv 
Men1+/-mice had simultaneous occurrence of insulin 
and glucagon-expressing tumours, although tumours 
co-expressing both hormones were not found. There was 
no significant difference in the occurrence of insulin-
Figure 1
Age of tumour occurrence in endocrine organs of 
male and female congenic Men1+/- mice. The 
pituitary, pancreas, adrenals and gonads, which 
have previously been reported (19) to have 
significantly altered tumour development in 5- to 
26-month-old 129S6/SvEv and C57BL/6 Men1+/- 
mice, were macroscopically examined for tumour 
development in four different age groups (5–8 
months, 9–17 months, 18–20 months and 21–26 
months) of Men1+/- mice, with the number (n) of 
mice per group. Differences in the of age of 
tumour development in 129S6/SvEv compared to 
C57BL/6 Men1+/- mice were assessed by 
Chi-squared test for trend.
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expressing PNETs between the two mouse strains (129S6/
SvEv Men1+/- vs C57BL/6 Men1+/- mice = 80% vs 93%) (Fig. 
3B). However, glucagon-expressing tumours developed 
significantly more frequently in the 129S6/SvEv Men1+/-  
mice than in C57BL/6 Men1+/- mice (7/10 mice vs 1/15 
mice, respectively; P < 0.002, Fig. 3B), such that glucagon-
expressing tumours of the 129S6/SvEv Men1+/- mice 
accounted for 37% (13/35) of the total PNETs, whereas 
glucagon-expressing tumours of C57BL/6 Men1+/- mice 
accounted for only 2% (1/43) of all PNETs (P < 0.0001).
Adrenal tumours in 129S6/SvEv and C57BL/6 
Men1+/- mice
Adrenal tumours were detected from 12 to 15 months 
of age in male and female 129S6/SvEv Men1+/- mice, 
respectively, but from 19 and 18 months of age in male 
and female C57BL/6 Men1+/- mice, respectively, thereby 
indicating a significant earlier age for development of 
adrenal tumours in the 129S6/SvEv Men1+/- mice than the 
C57BL/6 Men1+/- mice (P < 0.0005, Fig. 1). Furthermore, 
the occurrence of adrenal tumours in male 129S6/SvEv 
Men1+/- mice was significantly higher than that in the 
male C57BL/6 Men1+/- mice (31.1% vs 11.6%, respectively, 
P < 0.05; Table 1), while the overall occurrence of adrenal 
tumours in female Men1+/- mice was similar at all ages 
between both strains (Table 1). Immunohistochemical 
analysis of adrenal tumours (n = 4) indicated these 
tumours to arise from the adrenal cortex and confirmed 
loss of menin expression (Fig. 4A).
Gonadal tumours in 129S6/SvEv and C57BL/6 
Men1+/- mice
Ovarian tumours were detected from 12 months of age 
in 129S6/SvEv Men1+/- mice and from 17 months of age 
in C57BL/6 Men1+/- mice, which was not statistically 
significantly different (Fig. 1). However, the occurrence 
of ovarian tumours was higher in 129S6/SvEv Men1+/-  
mice compared to that in the C57BL/6 Men1+/-  
mice (32.4% vs 10.8%, respectively, P < 0.005; Table 1). 
Immunohistochemical analysis confirmed the loss 
of menin in these tumours (Fig. 4B). The occurrence 
of testicular tumours was not statistically significant 
different between the two strains (Table 1), but they were 
detected earlier in male 129S6/SvEv Men1+/- mice than 
C57BL/6 Men1+/- mice (12 vs 18 months of age (P < 0.005, 
Fig. 1). Immunohistochemical analysis confirmed the loss 
of menin in these tumours (Fig. 4C).
Genetic variants present in C57BL/6 Men1+/- mice 
compared to 129S6/SvEv Men1+/- mice
To identify potential genetic modifiers contributing to 
the observed phenotypic differences in the C57BL/6 vs 
129S6/SvEv Men1+/- mice, WGS was performed. A total 
of 54,845 genetic variants in 304 different genes were 
identified between C57BL/6 and 129S6/SvEv Men1+/- mice 
(Table 2). The variants were located in exons, introns 
(including splice regions), 3′ UTRs and 5′ UTRs, as well as 
upstream and downstream of gene loci (Table 2). Variants 
in the exonic regions included two nonsense variants 
Figure 2
Histological and immunohistochemical analysis of anterior pituitary 
tumours in congenic Men1+/- mice. Serial sections of anterior pituitary 
adenomas from 18-month-old Men1+/- 129S6/SvEv and C57BL/6 mice were 
stained with haematoxylin and eosin (H&E) and for menin, prolactin, 
growth hormone and chromogranin A, which is a neuroendocrine 
secretory protein (44). Menin expression was lost within the pituitary 
adenomas (t), whereas prolactin, growth hormone and chromogranin A, 
identified by brown DAB staining, were all expressed within cells of the 
anterior pituitary adenomas in both mouse strains. These findings 
indicate that the tumours are adenomas originating from the anterior 
pituitary and that they are associated with loss of menin expression. The 
scale bar represents 100 μM.
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in the Coenzyme Q7 (Coq7, Trp226Stop (W226*)) and 
dystrophia myotonica protein kinase (Dmpk, Tyr558Stop 
(Y558*)) genes, which were present in 129S6SvEv Men1+/-  
mice but not C57BL/6 Men1+/- mice. However, assessment 
of evolutionary conservation across mouse and human 
genomes revealed that the location of the variant in Coq7 
only occurs in one transcript that is not present in humans 
and that the C terminal of the encoded protein from the 
mouse Dmpk transcript (547–582) only shares 14% identity 
with the human protein. This lack of conservation indicates 
that these variants are unlikely to be genetic modifiers of 
the MEN1 gene. In addition to the nonsense variants, 285 
missense variants, 217 5′ UTR variants, 123 splice region 
variants and 1287 3′ UTR variants were identified within 216 
different genes. PANTHER analysis was used to identify the 
functional classification of these genes, and this indicated 
that variants were present in many genes within tumour-
associated cellular pathways including: cell cycle regulation 
(cyclin E2 (Ccne2)); Ras signalling (Kirsten rat sarcoma viral 
oncogene homologue (Kras)); wnt signalling (wingless-
type MMTV integration site family member 2B (Wnt2b)); 
interleukin signalling (Interleukin-3 receptor subunit alpha 
(Il3ra)) and apoptosis signalling (TNF receptor superfamily 
member 10a (Tnfrsf10a)) (Supplementary Table 3). These, 
together with Coq7 and Dmpk, were therefore selected for 
further study. The expression of these genes was evaluated 
by qRT-PCR in pituitary, pancreatic islets and gonadal 
tissues from Men1+/+ C57BL/6 and 129S6/SvEv mice. This 
did not reveal significant differences in the expression of 
any of these genes in the pancreatic islets (Fig. 5A and B) 
or gonadal tissue (Fig. 5C and D) in either male or female 
129S6/SvEv mice, when compared to C57BL/6 mice. In the 
pituitary, no significant difference was observed in Ccne, 
Wnt2b, Il3ra, Tnfrsf10a, Coq7 or Dmpk expression in either 
male or female 129S6/SvEv mice, compared to C57BL/6 mice 
(Fig. 5A and B). However, significantly higher expression 
of Kras was detected in the pituitaries of male 129S6/SvEv 
Men1+/+ mice, when compared to male C57BL/6 Men1+/+ 
mice (4-fold, P < 0.005, Fig. 5E); such significant differences 
were not detected in Kras expression in female Men1+/+  
mice (Fig. 5F). These findings suggest that Kras may be a 
potential modifier of Men1, and it is interesting to note that 
KRAS has been reported to suppress growth in pancreatic 
endocrine cells and that this is influenced by expression of 
menin (28). We therefore further investigated KRAS protein 
expression in the pituitaries of male Men1+/+ 129S6/SvEv and 
C57BL/6 mice by Western blot and immunohistochemistry 
analyses. Overall expression of the KRAS protein was very 
low and significant differences in KRAS protein expression 
were not detected (Fig. 5G, H and I).
Figure 3
Histological and immunohistochemical analysis of PNETs in congenic 
Men1+/- mice. (A) Serial sections of pancreatic islet tumours from 25 
≥18-month-old Men1+/- 129S6/SvEv and C57BL/6 mice were stained with 
haematoxylin and eosin (H&E) and for menin, insulin, glucagon, and 
chromogranin A. Menin expression, indicated by brown DAB staining, was 
observed in normal islets (n) and normal surrounding exocrine tissue, 
whereas pancreatic islet adenomas showed loss of menin expression (t). 
Tumours with loss of menin expression (t), predominantly expressed 
either insulin (i) or glucagon (g). The tumours also immunostained for 
chromogranin A (c), confirming their neuroendocrine origin. The scale bar 
represents 100 μM. (B) There was no significant difference in the 
development of insulin-expressing PNETs between 129S6/SvEv Men1+/- 
mice and C57BL/6 Men1+/- mice, but a significantly greater number of 
129S6/SvEv Men1+/- mice developed glucagon-expressing PNETs, when 
compared to C57BL/6 Men1+/- mice (**P < 0.005 using a Fishers exact test).
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Discussion
Our results reveal that genetic background significantly 
influenced the development of pituitary (Fig. 1 and Table 1), 
glucagon-expressing pancreatic (Fig. 3), adrenal and gonadal 
tumours (Fig. 1 and Table 1) in Men1+/- mice, which represent 
a model for the MEN1 syndrome, thereby supporting the 
role for genetic modifiers in altering the phenotype of this 
autosomal dominant disorder. These genetic modifiers may 
form part of the tumourigenic pathways, as suggested by 
our WGS analysis, and further analysis of these may provide 
important clues about the biological roles of these genes in 
cell cycle regulation and apoptosis in endocrine cells. In 
addition, identification of these genetic modifiers and their 
roles may help to provide explanations for the heterogeneity 
and age-related penetrance of MEN1, as well as identifying 
tumour-associated pathways that may be targeted by anti-
proliferative compounds.
Our studies of genetic background on endocrine 
tumour formation in adult Men1+/- mice has revealed 
that the tumours observed and their age of onset, in 
the 129S6/SvEv and C57BL/6 congenic Men1+/- mouse 
strains, were comparable to that in the same model on 
a mixed 129S6/SvEv and C57BL/6 background, with less 
than five consecutive backcrosses since the generation 
of the original chimera (19) to that described in other 
reported Men1 conventional mouse knockout models on 
a pure 129S6/SvEv background (29) or mixed backgrounds 
(Supplementary Table 4) (19, 30, 31). In each model, 
pancreatic NETs developed earliest and most frequently, 
with all models also developing the range of tumours seen 
in our congenic strains, with the exception of one model, 
which was on a mixed NIH Black Swiss and 129/SvEvTacFBR 
Table 2 Genetic variants identified in C57BL/6 Men1+/- mice 
compared to 129S6/SvEv Men1+/- mice, by whole genome 
sequencing. In total 54,845 variants were identified.
Variant type Number of variants
5′ UTRa 217
Intronic/intergenic 46,206
 Splice region 123
Exonic
 Non-coding 13
 Synonymous 574
 Missense 285
 Nonsense 2
3′ UTRa 1287
Upstream gene 3221
Downstream gene 2917
Total 54,845
aUTR, untranslated region.
Figure 4
Histological and immunohistochemical analysis of adrenal, ovarian and 
testicular tumours from congenic Men1+/- mice. (A) Adrenal cortical 
tumours from 23-month-old male 129S6/SvEv Men1+/- and C57BL/6 
Men1+/- mice were stained with haematoxylin and eosin (H&E) and for 
menin. In both strains, menin expression was lost in the tumours. The 
scale bar represents 100 μM. (B) Ovarian tumours from 18-month-old 
female Men1+/- 129S6/SvEv and C57BL/6 mice were stained with H&E and 
menin. Menin, identified by brown nuclear DAB staining (*), was lost in 
the tumours (t) and retained in the surrounding normal tissue. The scale 
bar represents 100 μM. (C) Testicular tumours from 18-month-old male 
Men1+/- 129S6/SvEv and C57BL/6 mice were stained with H&E and menin. 
In both strains, menin expression was lost in the tumours. The scale bar 
represents 100 μM.
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background and did not report the development of gonadal 
tumours (Supplementary Table 4) (31). Unlike previous 
reports, our study compares mouse models maintained on 
two different background strains and is therefore able to 
assess the effects of genetic background on the phenotypic 
manifestations of Men1 knockout.
The frequency of pituitary tumour development in 
female 129S6/SvEv Men1+/- mice over 12 months of age 
in our study was consistent with that of another 129S6/
SvEv model (29) (38% vs 32%, respectively), while the 
significantly increased frequency of pituitary tumours in 
female C57BL/6 Men1+/- mice (75.7%) is consistent with a 
previous C57BL/6 mouse study (77.8%) (30). Our results 
were also consistent with those reporting an increased 
occurrence of pituitary tumours in female mice, compared 
to males (19, 29). Thus, genetic background is an 
important determinant of pituitary tumour development 
in Men1+/- mice. We also show that tumour development is 
not just accelerated in the C57BL/6 model, as we observed 
a significant increase in the occurrence of adrenal and 
ovarian tumours in the 129S6/SvEv, when compared to the 
C57BL/6 Men1+/- mice. Differences in tumour development 
between strains were also not limited to one sex, since 
male 129S6/SvEv Men1+/- mice developed significantly 
more adrenal tumours than C57BL/6 Men1+/- mice, 
while significantly more female 129S6/SvEv Men1+/- mice 
developed ovarian tumours compared to female C57BL/6 
Men1+/- mice. The influence of genetic background on 
tumour phenotype may therefore explain the differences 
observed in four previously reported Men1+/- conventional 
mouse models; for example, gastric neuroendocrine 
tumours were reported only in a mixed NIH Black Swiss 
and 129/SvEvTacFBR model (Supplementary Table 4) 
(19, 29, 30, 31).
Figure 5
Expression of tumour-associated pathway genes 
with sequence variants observed in 129S6/SvEv 
and C57BL/6 mice. (A, B, C, D, E, and F) qRT-PCR 
was used to evaluate the expression of seven 
genes (Kras, Ccne2, Wnt2b, Tnfrsf10b, Il3ra, Coq7 
and Dmpk) in pancreatic islet (A and B), gonadal  
(C and D) and pituitary (E and F) tissue harvested 
from male and female WT (Men1+/+) 129S6/SvEv 
and C57BL/6 mice. Data are represented as mean 
and s.e.m.; relative to one 126S6/SvEv mouse; n = 4 
mice per group; **P < 0.005. (G) Western blot 
analysis of KRAS expression in male pituitary 
tissue harvested from Men1+/+ 129S6/SvEv and 
C57BL/6 mice; calnexin was used as a 
housekeeper. (H) KRAS expression from the 
Western blots was quantified using densitometry 
analysis. Data are represented as mean and s.e.m.; 
n = 4 mice per group. (I) Immunohistochemical 
analysis of KRAS expression in sections of male 
Men1+/+ 129S6/SvEv and C57BL/6 mice showing 
very low expression in PNET tissues. All images 
were taken using a ×20 objective, with the scale 
bar representing 100 μM.
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We observed no significant differences in the proportion 
of mice developing pancreatic islet tumours; however, 
129S6/SvEv mice developed significantly more glucagon-
expressing tumours, which did not express insulin, than 
the C57BL/6 strain. In normal mouse pancreatic islets, 
α-cells are located on the periphery of the islet secrete 
glucagon, whereas β-cells are located at the centre of the 
islet secrete insulin, and hence, it would be expected that 
glucagonomas would arise from α-cells and insulinomas 
from β-cells. However, studies of an α-cell specific Men1 
knockout mouse model produced on a mixed genetic 
background that included the C57BL/6 mouse strain have 
reported that mice developed both glucagonomas and 
insulinomas (32, 33). In MEN1 patients, it has also been 
shown that early onset pancreatic microadenomas with 
loss of heterozygosity (LOH) of MEN1 express glucagon, 
whereas more advanced hormone-secreting tumours in 
the same patients were predominantly insulinomas (34, 
35). Thus, it seems possible that the Men1+/- C57BL/6 
mice, in our study, had more advanced PNETs, when 
compared to 129S6/SvEv Men1+/- mice, which would 
have less advanced lesions. Detailed investigations of 
proliferation index using Ki67 staining or longitudinal 
proliferation studies using bromodeoxyuridine (BrdU) 
may help to clarify this. Another possibility is that the 
genetic background and any modifier genes may instead 
influence the cell types giving rise to the PNETs, and this 
may explain the absence of significant differences in the 
number of pancreatic tumours that occur at any age in the 
two mouse strains (Fig. 1 and Table 1).
The lack of genotype-phenotype correlation in MEN1 
patients (1) may involve roles for modifier genes. Thus, loss 
of menin expression is a pre-requisite for tumourigenesis; 
however, genes involved in the same proliferative and 
apoptotic tumourigenic pathways may act as modifiers. 
Identifying such MEN1 modifiers is of particular 
importance, as it may provide a tool for predicting tumour 
manifestations in MEN1 patients, as well as providing 
novel targets for both mono- and combination-drug 
therapies. Our WGS analysis identified >54,000 variants, 
within >300 genes between 129S6/SvEv Men1+/- mice and 
C57BL/6 mice Men1+/- mice, which could represent Men1 
genetic modifiers. In silico functional analysis revealed 
variants in genes associated with tumourigenic pathways, 
including Kras, Wnt2b, Il3ra and Tnfrsf10a, which were 
associated with Kras, wnt, interleukin and apoptosis 
signalling, respectively. These genes have potential to be 
MEN1 modifiers, as the Men1 protein product, menin, 
has been shown to: repress MAPK-driven proliferation 
downstream of KRAS (28), control wnt signalling through 
interaction with β-catenin (36, 37, 38), regulate expression 
of interleukins (39) and promote TNF-α induced apoptosis 
through up-regulation of caspase 8 (40). In addition, an 
association between a cyclin dependent kinase inhibitor 
1B (Cdkn1b) variant (c.326T>G) and tumour multiplicity 
in MEN1 patients has been reported (41), although we did 
not observe any variants in Cdkn1b (encoding p27kip1) in 
our WGS data, we did observe variants in the cell cycle 
regulator, Ccne2, that is regulated by p27kip1. Ccne2 encodes 
cyclin E2 which, when in complex with cyclin dependent 
kinase 2 (Cdk2), is inhibited by p27kip1, and it has been 
demonstrated that cyclin E-Cdk2 substrates may vary in 
different cell types (42). In contrast, however, it has been 
reported that MEN1 tumourigenesis in the pituitary and 
pancreatic islet requires Cdk4 but not Cdk2 (43).
Investigation of candidate modifier genes expression 
in WT C57BL/6 and 129S6/SvEV mice showed significant 
differences only in Kras expression in male pituitary tissue. 
It has been reported that KRAS can suppress pancreatic 
endocrine cell growth and that inhibition of proliferation 
by KRAS is dependent on the RAS effector protein RASSF1A 
and inhibition of the downstream mitogen-activated 
protein kinase (MAPK) signalling pathway by menin 
(28). Therefore, variants in KRAS could influence menin-
associated proliferative pathways. Our studies revealed that 
Kras transcription was significantly decreased in C57BL/6 
Men1+/+ male pituitaries, when compared to pituitaries 
of Men1+/+ male 129SvEv mice (Fig. 5E), although no 
significant changes could be detected in KRAS protein 
levels. This discrepancy may be due to variability in KRAS 
protein translation and protein stability. Furthermore, 
as changes in KRAS transcripts were only detected in the 
pituitary but not in the pancreatic islets or gonads (Fig. 5A, 
B, C, D, E and F), it is possible that different genes may 
modify tumour development, in a tissue-specific manner. 
Thus, our studies have identified possible roles for Kras, 
Wnt2b, Il3ra and Tnfrsf10a as potential MEN1 genetic 
modifiers, and further, more detailed in vitro and in vivo 
studies will help to clarify their biological roles in MEN1 
tumourigenesis.
In summary, our results demonstrate that genetic 
background alters the phenotypic expression of PNETs 
and pituitary, adrenal and ovarian tumours due to loss 
of Men1, thereby providing a model that will help to 
improve our understanding of the clinical manifestations 
of MEN1 mutations in different patients.
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